CAIV-T vaccine regulatory update

FDA's Vaccines and Related Biological Products Advisory Committee voted in favor of expanding the label of CAIV-T intranasal influenza vaccine to include

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE